
ADVOCACY THE MYOSITIS ASSOCIATION (TMA) CLINICAL TRIAL LISTING

If You Have Myositis And Lupus, You May Qualify For A Research Study

Bristol-Myers Squibb is currently sponsoring a research study for patients with systemic lupus erythematosus (SLE). People diagnosed with lupus can sometimes also develop myositis, an inflammation of the skeletal muscles that causes weakness and loss of strength. Lupus myositis often affects the muscles of your neck, pelvis, thighs, shoulders, and upper arms.

The Paisley Study is evaluating an oral investigational drug, BMS-986165, to see if it may lessen symptoms of systemic lupus erythematosus (SLE) and reduce the amount of steroids patients may need. You may even be able to continue taking your current lupus and/or myositis medication along with the investigational drug.

To qualify you must be 18-75 years old, diagnosed with moderate to severe systemic lupus erythematosus for 6 months or more, and currently taking medication for lupus. You may also have an overlapping diagnosis of myositis disease. Those who qualify and choose to participate may receive the investigational drug and all study-related assessments at no cost, be monitored by a lupus study team and be reimbursed for any reasonable expenses incurred while participating.

Visit PaisleyStudy.com to learn more today.

**Below is the text to be displayed in the search results in the TMA Clinical Trial Search tool

Name	Eligible	Study Sites	More Information
BMS-986165, an oral tyrosine kinase 2 (Tyk2) for systemic lupus erythematosus (SLE).	Adults between ages 18 and 75, meets the SLICC Classification for SLE, may have myositis overlap	69 different sites in the United States, 181 sites spread out around 18 countries	More details [TMA Trial Listing web link]; NCT03252587